Despite the strong targeting and demonstrated efficacy in combination therapy for osteosarcoma, Mabs targeting VEGF or other proangiogenic factors face limitations in clinical application due to their high cost, uncertain survival benefit, and side effects (148–150). This evidence concerns the gene VEGFA and osteosarcoma.